DUOPHARMA BIOTECH BERHAD

KLSE: 7148 (DPHARMA)

Last update: 25 minutes ago

1.34

-0.01 (-0.74%)

  • 1D -0.74%
  • 5D -2.90%
  • 1M 4.69%
  • 6M 7.20%
  • YTD 6.35%
  • 1Y 8.06%
  • 5Y 5.10%
Previous Close 1.35
Open 1.36
Volume 1,258,400
Avg. Volume (3M) 638,623
Market Cap 1,289,002,368
Price / Earnings (TTM) 16.75
Price / Earnings (Forward) 14.08
Price / Sales 1.50
Price / Book 1.87
52 Weeks Range
1.07 (-20%) — 1.46 (8%)
Earnings Date 13 Aug 2025 - 18 Aug 2025
TTM Dividend Yield 2.24%
Profit Margin 8.26%
Operating Margin (TTM) 14.69%
Diluted EPS (TTM) 0.080
Quarterly Revenue Growth (YOY) 36.20%
Quarterly Earnings Growth (YOY) 67.80%
Total Debt/Equity (MRQ) 70.73%
Current Ratio (MRQ) 3.83
Operating Cash Flow (TTM) 114.27 M
Levered Free Cash Flow (TTM) 53.91 M
Return on Assets (TTM) 5.22%
Return on Equity (TTM) 10.48%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - Specialty & Generic (MY) Mixed Mixed
Drug Manufacturers - Specialty & Generic (Global) Bearish Mixed
Stock DPHARMA Bullish Bullish

AIStockmoo Score

0.9
Analyst Consensus 5.0
Insider Activity NA
Price Volatility -1.5
Technical Moving Averages -2.5
Technical Oscillators 2.5
Average 0.88

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
DPHARMA 1 B 2.24% 16.75 1.87
YSPSAH 326 M 4.78% 13.53 0.770
RHONEMA 137 M 4.03% 15.50 0.800
PLABS 110 M - 40.00 1.27

Duopharma Biotech Bhd is an investment holding company engaged in manufacturing pharmaceuticals. It develops, manufactures, and markets generic and over-the-counter pharmaceutical products. The operating segment of the company is the manufacturing and distribution of pharmaceutical products. The principal activities of its subsidiary are to carry out business as a manufacturer, distributor, importer, and exporter of pharmaceutical products and medicines. Geographically, the company generates the majority of its revenue from Malaysia.
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Investment Style Small Core
% Held by Insiders 2.64%
% Held by Institutions 71.90%

Ownership

Name Date Shares Held
Billion Victory Sdn Bhd 31 Mar 2023 15,070,000 (1.57%)
Manulife Investment Shariah Progress Fund 31 Oct 2022 8,670,000 (0.90%)
52 Weeks Range
1.07 (-20%) — 1.46 (8%)
Price Target Range
1.56 (16%) — 1.70 (26%)
High 1.70 (TA, 26.87%) Buy
Median 1.63 (21.64%)
Low 1.56 (RHB, 16.42%) Buy
Average 1.63 (21.64%)
Total 2 Buy
Avg. Price @ Call 1.35
Firm Date Target Price Call Price @ Call
RHB 06 Jun 2025 1.56 (16.42%) Buy 1.38
16 May 2025 1.50 (11.94%) Buy 1.29
TA 21 May 2025 1.70 (26.87%) Buy 1.32
16 May 2025 1.70 (26.87%) Buy 1.29

No data within this time range.

  • 3M
Date Type Details
06 Jun 2025 TheEdge Duopharma's sales to public sector could moderate in coming months, Kenanga says
06 Jun 2025 TheEdge UOB Kay Hian cuts earnings, keeps FBM KLCI target at 1,620 on 2H2025 recovery hopes
04 Jun 2025 TheEdge Kenanga lowers KLCI’s end-2025 target to 1,655, halves earnings forecast after weak 1Q
29 May 2025 Announcement Change in Audit Committee - DR HASNITA BINTI HASHIM
29 May 2025 Announcement CHANGE IN THE STRUCTURE AND COMPOSITION OF THE BOARD COMMITTEES OF DUOPHARMA BIOTECH BERHAD
29 May 2025 Announcement Change in Boardroom - DR HASNITA BINTI HASHIM
23 May 2025 Announcement Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - EMPLOYEES PROVIDENT FUND BOARD
22 May 2025 Announcement Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - EMPLOYEES PROVIDENT FUND BOARD
21 May 2025 Announcement Duopharma Biotech Maintains Focus on Domestic Market Leadership and International Growth
21 May 2025 Announcement Change in Boardroom - DATUK NIK MOUSTPHA BIN HAJI NIK HASSAN
21 May 2025 TheEdge Duopharma sees stronger halal product demand from Indonesia amid policy support
21 May 2025 TheSun Duopharma Biotech targets more halal exports to Indonesia
21 May 2025 TheSun Duopharma eyes Indonesia for halal product growth
21 May 2025 Announcement Change in Boardroom - DATUK WIRA ARHAM BIN ABDUL RAHMAN
21 May 2025 Announcement Change in Boardroom - DATO ADNAN HISHAM BIN PAWANTEH
21 May 2025 Announcement Change in Boardroom - DR SHARMILA A/P RAMACHANDRAN
21 May 2025 Announcement Change in Audit Committee - ENCIK RAZALEE BIN AMIN
21 May 2025 Announcement Change in Audit Committee - PUAN NIK FAZILA BINTI NIK MOHAMED SHIHABUDDIN
21 May 2025 Announcement Change in Audit Committee - PUAN ZAITON BINTI JAMALUDDIN
21 May 2025 Announcement Change in Audit Committee - DR SHARMILA A/P RAMACHANDRAN
21 May 2025 Announcement Change in Nomination and Remuneration Committee - DATO' DR ZAKI MORAD BIN MOHAMAD ZAHER
21 May 2025 Announcement Change in Risk Committee - DATUK MOHD RADZIF BIN MOHD YUNUS
21 May 2025 Announcement Change in Risk Committee - DATO' EISAH BINTI A. RAHMAN
21 May 2025 Announcement Change in Risk Committee - PUAN ZAITON BINTI JAMALUDDIN
21 May 2025 Announcement Change in Risk Committee - DATUK NIK MOUSTPHA BIN HAJI NIK HASSAN
21 May 2025 Announcement Change in Risk Committee - DATUK WIRA ARHAM BIN ABDUL RAHMAN
21 May 2025 Announcement Change in Risk Committee - DR SHARMILA A/P RAMACHANDRAN
21 May 2025 Announcement CHANGE IN THE STRUCTURE AND COMPOSITION OF THE BOARD COMMITTEES OF DUOPHARMA BIOTECH BERHAD
21 May 2025 Announcement General Meetings: Outcome of Meeting
21 May 2025 Announcement Change in Boardroom - DATO' DR ZAKI MORAD BIN MOHAMAD ZAHER
21 May 2025 Announcement Change in Boardroom - ENCIK RAZALEE BIN AMIN
21 May 2025 Announcement Change in Boardroom - PUAN ZAITON BINTI JAMALUDDIN
21 May 2025 Announcement Change in Nomination and Remuneration Committee - DATUK WIRA ARHAM BIN ABDUL RAHMAN
20 May 2025 Announcement AGREEMENT FOR THE PROCUREMENT VIA DIRECT NEGOTIATION FOR THE SUPPLY OF INSULIN MEDICINE AS A PACKAGE ('PERJANJIAN PEROLEHAN SECARA RUNDINGAN TERUS PEMBEKALAN UBAT INSULIN RECOMBINANT HUMAN 100IU/ML PENFILL/REFILL SECARA PAKEJ') PURSUANT TO THE ACCEPTANCE OF TENDER OFFER FOR THE SUPPLY OF RECOMBINANT HUMAN INSULIN FORMULATIONS (HEREINAFTER REFERRED TO AS THE "PRODUCTS") TO THE GOVERNMENT OF MALAYSIA
20 May 2025 Announcement Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - EMPLOYEES PROVIDENT FUND BOARD
20 May 2025 TheEdge MOH grants Duopharma six-month contract extension for insulin supply
19 May 2025 Announcement MATERIAL LITIGATION
15 May 2025 Announcement Revised Administrative Guide
15 May 2025 TheEdge Duopharma posts record-high 1Q profit on strong sales, active ingredient price normalisation
15 May 2025 Announcement Quarterly rpt on consolidated results for the financial period ended 31/03/2025
15 May 2025 Announcement Duopharma Biotech Records 36.2% Revenue Growth and 67.8% Profit Improvement in Q1 FY2025
14 May 2025 Announcement Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - EMPLOYEES PROVIDENT FUND BOARD
13 May 2025 Announcement Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - EMPLOYEES PROVIDENT FUND BOARD
13 May 2025 TheEdge Duopharma set for strong 1Q growth backed by approved products purchase list contracts — CGS International
28 Apr 2025 TheEdge Duopharma bags another supply contract from Pharmaniaga
28 Apr 2025 TheEdge Dividend stocks regain appeal as global uncertainty looms
28 Apr 2025 TheEdge Nestlé Malaysia, Bursa Malaysia, BAT Malaysia, F&N, Rohas Tecnic, MKH, Meta Bright, Duopharma Biotech, Pintaras Jaya, Johor Plantations
28 Apr 2025 Announcement CONTRACTS FOR THE SUPPLY BY DUOPHARMA (M) SENDIRIAN BERHAD, DUOPHARMA MANUFACTURING (BANGI) SDN. BHD. AND DUOPHARMA HAPI SDN. BHD. (ALL WHOLLY-OWNED SUBSIDIARY COMPANIES OF DUOPHARMA BIOTECH BERHAD), THROUGH PHARMANIAGA LOGISTICS SDN. BHD. OF PHARMACEUTICAL AND/OR NON-PHARMACEUTICAL PRODUCTS FOR THE MINISTRY OF HEALTH OF MALAYSIA UNDER THE APPROVED PRODUCTS PURCHASE LIST (Announcement pursuant to Chapter 9 of Bursa Malaysia Securities Berhad Main Market Listing Requirements)
21 Apr 2025 Announcement Annual Report & CG Report - 2024
21 Apr 2025 Announcement Annual Audited Accounts - 31 Dec 2024
18 Apr 2025 Announcement General Meetings: Notice of Meeting
17 Apr 2025 TheEdge Cover Story: Healing old wounds and growing new income streams at Pharmaniaga
10 Apr 2025 TheEdge Cover Story: Risk-off mode likely to continue in 2Q on continuous foreign fund outflows
09 Apr 2025 Announcement CONTRACT FOR THE SUPPLY BY DUOPHARMA HAPI SDN. BHD. (A WHOLLY-OWNED SUBSIDIARY COMPANY OF DUOPHARMA BIOTECH BERHAD), THROUGH PHARMANIAGA LOGISTICS SDN. BHD. OF PHARMACEUTICAL AND/OR NON-PHARMACEUTICAL PRODUCTS FOR THE MINISTRY OF HEALTH OF MALAYSIA UNDER THE APPROVED PRODUCTS PURCHASE LIST (Announcement pursuant to Chapter 9 of Bursa Malaysia Securities Berhad Main Market Listing Requirements)
09 Apr 2025 TheEdge Duopharma Biotech bags supply contracts worth RM16.58m from govt in third round of award
02 Apr 2025 TheEdge Duopharma Biotech back on growth path as focus on revenue pays off
28 Mar 2025 Announcement Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - EMPLOYEES PROVIDENT FUND BOARD
26 Mar 2025 TheEdge Special Report: Malaysia not ready for another pandemic, say health experts
Show more
TTM Dividend Yield 2.24%
5Y Average Dividend Yield 2.31%
Payout Ratio 39.53%
Expected Next Dividend Payment Sep 2025
Ex Date Announcement Date Payment Date Details
05 Mar 2025 19 Feb 2025 19 Mar 2025 0.02 Cash
29 Aug 2024 15 Aug 2024 12 Sep 2024 0.01 Cash
07 Mar 2024 22 Feb 2024 21 Mar 2024 0.018 Cash
08 Sep 2023 24 Aug 2023 22 Sep 2023 0.005 Cash
07 Apr 2023 27 Mar 2023 09 May 2023 0.018 Cash
29 Aug 2022 16 Aug 2022 14 Sep 2022 0.005 Cash
14 Apr 2022 24 Mar 2022 13 May 2022 0.018 Cash
30 Aug 2021 17 Aug 2021 15 Sep 2021 0.005 Cash
21 Apr 2021 08 Apr 2021 21 May 2021 0.06 Cash
28 Aug 2020 13 Aug 2020 11 Sep 2020 0.005 Cash
13 Jul 2020 30 Jun 2020 12 Aug 2020 0.05 Cash
15 Oct 2019 02 Oct 2019 14 Nov 2019 0.01 Cash
26 Jun 2019 13 Jun 2019 26 Jul 2019 0.04 Cash
02 Nov 2018 22 Oct 2018 23 Nov 2018 0.015 Cash
13 Jun 2018 31 May 2018 17 Jul 2018 0.06 Cash
17 Oct 2017 25 Aug 2017 10 Nov 2017 0.025 Cash
26 May 2017 24 Feb 2017 23 Jun 2017 0.04 Cash
19 Oct 2016 22 Aug 2016 11 Nov 2016 0.025 Cash
06 Jun 2016 23 Feb 2016 28 Jun 2016 0.055 Cash
13 Oct 2015 25 Aug 2015 06 Nov 2015 0.04 Cash
27 May 2015 24 Feb 2015 25 Jun 2015 0.145 Cash
15 Oct 2014 26 Aug 2014 07 Nov 2014 0.04 Cash
22 May 2014 26 Feb 2014 20 Jun 2014 0.135 Cash
14 Oct 2013 28 Aug 2013 08 Nov 2013 0.04 Cash
14 Jun 2013 22 Mar 2013 12 Jul 2013 0.105 Cash
15 Oct 2012 16 Aug 2012 09 Nov 2012 0.035 Cash
06 Jun 2012 16 Mar 2012 29 Jun 2012 0.145 Cash
05 Oct 2011 18 Aug 2011 28 Oct 2011 0.035 Cash
08 Jun 2011 21 Apr 2011 27 Jun 2011 0.11 Cash
06 Oct 2010 02 Sep 2010 28 Oct 2010 0.045 Cash
09 Jun 2010 21 Apr 2010 25 Jun 2010 0.12 Cash
01 Oct 2009 26 Aug 2009 23 Oct 2009 0.06 Cash
10 Jun 2009 15 Apr 2009 26 Jun 2009 0.07 Cash
08 Oct 2008 26 Aug 2008 28 Oct 2008 Interim Dividend
03 Oct 2007 24 Aug 2007 18 Oct 2007 Interim Dividend
29 May 2007 25 Apr 2007 08 Jun 2007 Final Dividend
11 Sep 2006 23 Aug 2006 22 Sep 2006 Interim Dividend
18 May 2006 24 Apr 2006 08 Jun 2006 First and Final Dividend
26 Jul 2005 06 Jun 2005 18 Aug 2005 Final Dividend
21 Oct 2004 06 Oct 2004 08 Nov 2004 Interim Dividend
06 Jul 2004 01 Jun 2004 28 Jul 2004 Final Dividend
26 Sep 2003 09 Sep 2003 20 Oct 2003 Interim Dividend
23 Jun 2003 25 Apr 2003 08 Jul 2003 First and Final Dividend
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2025 0.020 1 1.49
2024 0.028 2 2.24
2023 0.023 2 1.83
2022 0.023 2 1.43
2021 0.065 2 3.87
2020 0.055 2 2.17
2019 0.050 2 4.70
2018 0.075 2 10.53
2017 0.065 2 7.99
2016 0.080 2 12.57
2015 0.185 2 21.97
2014 0.175 2 29.38
2013 0.145 2 23.59
2012 0.180 2 35.47
2011 0.145 2 30.13
2010 0.165 2 28.97
2009 0.130 2 23.22
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria